Chemomab Therapeutics Ltd. (CMMB) Stock Ticker
Market factors today
Unlock the full CMMB picture
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB stock facts
| Ticker symbol | CMMB |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $13.3M |
| CEO | Adi Mor George |
| Employees | 12 |
| Headquarters | Tel Aviv-Yafo, TA, IL |
| IPO date | 2019-02-12 |
| Website | www.chemomab.com |
What you can see for CMMB on Tickr
Live CMMB price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the CMMB report.
Rankings
FAQ
What is the ticker symbol for Chemomab Therapeutics Ltd.?
The ticker symbol for Chemomab Therapeutics Ltd. is CMMB, listed on the NASDAQ Capital Market.
What is CMMB?
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for…